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Malaria is a life-threatening disease and the search for vaccine targets to the malaria 
parasite Plasmodium continues to be of utmost importance. Antibody mediated vaccines 
to the pre-erythrocytic stage of Plasmodium represent the best opportunity for vaccine 
development due to the potential to stop or decrease the number of sporozoites that reach 
the liver and trigger symptomatic disease. Plasmodium sporozoites are actively motile and 
this motility is critical to their infectivity. Inhibition of gliding has been used to assess 
whether particular surface proteins of the sporozoite good vaccine targets. We present a 
method that can be used to assess antibody mediated inhibition of gliding motility by 
quantifying the fluorescence intensity of the trails that sporozoites leave behind as they 
move. We demonstrate the functionality of the assay with the human malaria parasite 
Plasmodium falciparum and a known inhibitory monoclonal antibody 2A10. Our data 
suggests that the fluorescence intensity assay can be a useful in vitro method of assessing 
the efficacy of antigen based vaccines. Plasmodium surface proteins thrombospondin-
related anonymous protein (TRAP) and circumsporozoite protein (CSP) play important 
roles in sporozoite motility. CSP is the basis of the RTS,S malaria vaccine but the 
relationship between TRAP and CSP has yet to be fully illuminated.  We investigated the 
distribution of TRAP on the surface of wild type and Plasmodium berghei CSP repeat 
mutant sporozoites in gliding and non-gliding conditions. Our data suggests that there is a 
correlation between irregular gliding motility and decreased secretion of TRAP. 
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Malaria continues to be a life-threatening disease worldwide, causing approximately 
600,000 deaths and 200 million cases [10]. Malaria belongs to the genus Plasmodium and 
is caused by apicomplexan parasites that complete their life cycle in both mosquito and 
vertebrate hosts [4]. Plasmodium falciparum causes the largest number of fatal diseases 
but other species also play a role in illness including P. vivax, P. ovale curtisi, P. ovale 
wallikeri, P. malariae, and P. knowlesi [10]. In rodents, malaria species include P. berghei, 
P. yoelli, P. chabaudi, and P. vinckei.  
The malaria life cycle begins when an Anopheles mosquito bites a vertebrate hosts and 
takes a blood meal [10]. In doing so, the mosquito ingests Plasmodium gametocytes which 
then form gametes [3]. In the midgut of the mosquito, the female and male gametes fuse to 
form a fertilized zygote called an ookinete [3]. Ookinetes are motile and they invade the 
mosquito midgut and form oocysts [3]. The oocysts enlarge and eventually rupture, 
releasing the infectious stage of Plasmodium called sporozoites [12]. Sporozoites mature 
and invade the salivary glands of the mosquito where they are ready to be transmitted to 
another vertebrate host [12]. Transmission of sporozoites occurs when the mosquito probes 
the skin of the host with its proboscis looking for blood [3]. This probing causes sporozoites 
in mosquito saliva to be injected into the skin [12, 28, 31]. Once in the skin, sporozoites 
carry out a form of motion called gliding motility and invade blood vessels [4, 14]. 
Sporozoites in the blood are carried to the liver where they invade hepatocytes [3].  
Once Plasmodium has infected the liver, sporozoites develop into the exoerythocytic 
form of the parasite called schizonts [3]. Schizonts rupture and release thousands of 
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merozoites that invade erythrocytes [10]. In the red blood cells, merozoites develop into 
trophozoites which then form schizonts [10]. The release of merozoites and infection of 
red blood cells is cyclical, causing a large increase in parasite load [3]. This blood stage of 
infection causes clinical manifestations of malaria [10]. Merozoites form gametocytes that 
can then be ingested by more mosquitoes, continuing the spread of the parasite [10]. Our 
best chance at stopping the progression of malaria is preventing sporozoite invasion and 
traversal. Not only are there lower numbers of parasites at this stage but targeting invasion 
and traversal prevents the development and release of merozoites; this means that the blood 
stage of infection and potential life-threatening clinical disease are not given the 
opportunity to manifest. 
The only malaria vaccine that has shown potential in Phase III clinical trials is RTS,S, 
a pre-erythrocytic stage vaccine that targets circumsporozoite protein (CSP) on the surface 
of sporozoites [18]. CSP coats the entire surface of the sporozoite and is made up of an 
NH2-terminal domain, a central repeat region, and a C terminal thrombospondin repeat 
(TSR) [19]. The RTS,S vaccine is a fusion protein consisting of the CSP repeat region and 
the TSR adhesive domain fused to the surface antigen of hepatitis B [22]. The RTS,S 
vaccine induces an antibody response and has shown promise in protection against P. 
falciparum but this protection is not long lasting. In a phase III randomized, controlled trial 
conducted at 11 locations in Africa, young infants and children were administered 3 doses 
of either RTS,S/AS01 or a control vaccine [22]. Vaccine efficacy against clinical malaria 
(including severe disease or disease requiring hospitalization) was tracked for 18 months 
post immunization. Vaccine efficacy in children was shown to be 46% during the 18 
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months of the trial. Efficacy against severe disease or malaria hospitalization decreased to 
34% and 19% respectively during the 20th month post immunization [22]. Vaccine efficacy 
against clinical malaria was 27% in young infants [22], and even with a lower efficacy, a 
number of clinical malaria cases were avoided due to immunization, there was no 
significant protection against severe malaria or hospitalization [22]. Importantly, vaccine 
efficacy decreased over time for both children and young infants [22]. Therefore, although 
RTS,S is the gold standard for malaria vaccines, the search for other antigen targets to 
enhance the RTS,S vaccine continues. The PATH Malaria Vaccine Initiative’s HPATIC 
project, which our results contribute to, is a hypothesis-driven approach to finding non-
CSP sporozoite vaccine targets. 
 While the structure and function of CSP have been studied [8, 9, 19, 21], as of yet the 
exact role of the repeats is yet to be fully illuminated. A previous study has shown that 
mutant parasites that lack the repeat region are unable to produce functional sporozoites 
[13]. Since the deletion of the entire repeat sequence gives rise to a severe phenotype, our 
lab has generated CSP repeat mutants that allow sporozoites to develop but show different 
motility phenotypes than wild type parasites. Since CSP is shed as parasites move and 
TRAP has been shown to be necessary for gliding motility [11, 26], the relationship 
between CSP and TRAP in mutant parasites is of great interest. Here we explore the role 




GLIDING MOTILITY IN PLASMODIUM FALCIPARUM 
INTRODUCTION 
The PATH Malaria Vaccine Initiative HPATIC project began as a hypothesis 
driven approach to finding a pre-erythocytic stage vaccine for Plasmodium falciparum. A 
consortium of laboratories from Johns Hopkins University (JHU), the Center for Infectious 
Disease Research (CIDR), the Walter Reed Army Institute of Research (WRAIR), the 
National Institutes of Health (NIH), and the Naval Medical Research Center (NMRC) came 
together to determine the antigen candidates for vaccine development. 64 antigens were 
chosen by the consortium on a range of criteria that included biological rationale, observed 
in vivo protection in rodents, functional assay activity, sporozoite surface expression, 
putative functional domains, and human sera reactivity. Out of these 64 antigens, 24 were 
prioritized based on characteristics that would make them good vaccine targets (Fig. 1). 
Antigens that demonstrated multiple characteristics were of the highest priority (Fig. 1.).   
 
23 of the 24 antigens were expressed in vitro using a wheat germ system [23]. The 
24th antigen was broken up and 2 domains were expressed independently. Balb/c mice were 
immunized with the wheat germ antigens and polyclonal antibodies were obtained (Fig. 2). 
These antibodies were blinded and designated to random HEPA groups before being tested 
in multiple functional assays. These functional assays were performed by the labs that 
chosen the initial antigen vaccine candidates. JHU performed ELISA, permeabilized and 
live IFAs, and gliding motility assays. Invasion and traversal assays were carried out at 
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CIDR and ILSDA was performed by NMRC. Polyclonal antibodies that showed positive 
results in multiple functional assays were prioritized for the next stage of testing.  
The next stage involved making monoclonal antibodies in Kymice using the 
proteins that produced antibodies with activity in the above mentioned assays (Fig. 2). 
Kymice are transgenic and while their antibody genes have mouse constant regions, the 
variable regions have been replaced by the complete human immunoglobulin genes from 
three loci [29] so they produce humanized antibodies.    –  
 
In order to prioritize the mAbs to be tested, Atreca technology was used to sequence 
antibody genes [1]. Atreca sequences antibody heavy and light chains using next generation 
sequencing (NGS) and DNA barcoding [1]. This 454 deep sequencing technology pairs 
heavy and light antibody chains that originate from single B cells and measures clonal 
evolution and clonal proportions [1]. From the library of mAbs generated, JHU received 
118 antibodies from 11 different HEPA proteins for testing in gliding motility assays 
(Table 1).  
 
The gliding motility assay has often been used to assess antibody-mediated vaccine 
efficacy [8]. In this assay, P. falciparum sporozoites are incubated with an inhibitory 
antibody then added to wells pre-coated with 2A10 and allowed to glide. The CSP trails 
shed by the sporozoites when gliding can be stained with an antibody against CSP and then 
observed under a fluorescent microscope. The ability of the inhibitory antibody to limit 
gliding is inversely correlated with the number of CSP trails [24]. In the classic assay, 
gliding motility is quantified by counting the number of sporozoites associated with trails 
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and the number of circles present in each trail [24]. However, there are limitations to the 
classic gliding motility assay; it can be both time consuming and low throughput, 
particularly when faced with the challenge of testing 118 monoclonal antibodies. 
Categorizing the trails can also be subjective and it can be difficult to differentiate between 
see small differences in motility. We set out to develop a medium throughput method for 
quantifying gliding motility that would be able to differentiate between subtle differences 























Figure 1. Overview of the HPATIC project. 
  
24 antigens prioritized - target proteins expressed using in vitro wheat germ 
system 
64 antigens chosen by JHU, CIDR, WRAIR, NMRC, and NIH as potential 
vaccine candidates 
Balb/c mice immunized with wheat germ antigens and polyclonal sera obtained 
– polyclonal Abs were masked and designated to HEPA groups 
Polyclonal sera used in functional assays (ELISA, permeabilized and live IFA, 
gliding motility, invasion and cell traversal assay, ILSDA) 
 pAbs from 11 HEPA groups used to generate human monoclonal Abs in 
Kymice and mAbs were prioritized using Atreca technology 












ISI - inhibition of sporozoite invasion 
ILSDA - inhibition of liver stage 
development assay 
EM – electron microsocopy 
GPI - glycophosphoinositol 
PEXEL - Plasmodium export element 















Table 1. The monoclonal antibodies received by JHU for gliding motility assays split up 






Mosquito rearing and production of sporozoites 
NF54 gametocytes were used to produce P. falciparum sporozoites as described 
previously [29]. On day 16 post blood meal, sporozoites were isolated from mosquito 
salivary glands.  
 
Methods for gliding motility assay 
Glass coverslips were placed in a 24 well plate and coated with 10 µg/mL of 2A10 
in 1x PBS pH 7.4 overnight at room temperature. Solutions with twice the desired 
inhibitory antibody concentration were made in 200 µL of 6% BSA/DMEM pH 7.4. The 
dilutions were made in 0.5mL Eppendorf tubes.  Mosquitoes were dissected in DMEM 
(Dulbecco’s Modified Eagle Medium) and sporozoites were isolated and counted. 200 µL 
containing 50000 sporozoites in DMEM were added to the previously made antibody 
dilution to get a final volume 400 µL of 3% BSA/DMEM per condition. The Eppendorf 
tubes containing sporozoites were incubated in a gradient thermocycler at 25°C for 30 
minutes. Glass coverslips were washed 3 times with 1x PBS pH 7.4. Sporozoites were 
added to the washed coverslips and were spun for 4 minutes at 300g with an acceleration 
of 3 minutes and no brake deceleration. The 24 well plate was placed in a 5% CO2 
incubator for 1 hour to allow sporozoites to glide. The media was removed from the well 
and the sporozoites were fixed with 4% paraformaldehyde for 1 hour at room temperature. 
The wells were washed 3 times with 1x PBS pH 7.4. The wells were blocked with 
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1%BSA/5% goat serum/BSA for 1 hour at 37°C. The wells were then stained with primary 
antibody for 1 hour at 37°C, washed 3 times with PBS, and then stained with secondary 
antibody for 1 hour at 37°C. The main primary antibody used was biotinylated 2A10 (1:100 
dilution) followed by an Alexa fluor 488 conjugated streptavidin (1:500 dilution). The 
other primary used was an anti-C terminus of CSP antibody [16] (1:100 dilution) followed 
by a goat anti-rabbit IgG (H+L) highly cross adsorbed secondary conjugated to Alexa fluor 
488 (1:500 dilution) [A-11034] . After staining, the wells were washed 3 times with PBS. 
The coverslips were carefully removed from the wells, allowed to dry for 10 minutes, and 
then mounted to slides with ProLong Gold antifade DAPI mounting media overnight. The 
coverslips were then sealed with clear nail polish and imaged using the 40x oil objective 
of a fluorescent microscope.  
 
Fluorescence Intensity Assay  
The parameters on the program Nikon NIS Basic Research Elements were set as follows: 
40x nosepiece, 1280x1024 fast resolution, 1280x1024 16 bit quality, and high contrast. For 
the biotinylated 2A10 treated wells, the exposure time was 150ms. Due to increased 
background, the exposure time for the anti-C treated wells was 80 ms. 20 images spanning 
the entirety of the well were taken. To ensure random image acquisition, the microscope 
field of view was top to bottom on the left side of the well and 5 images were taken. The 
field of view was then moved to the right and 5 more images were taken. This process was 
repeated until 20 images were acquired. The sum fluorescence intensity from each image 




Classic gliding motility assay 
The number of sporozoites associated with trails was counted according to the 
following categories: 0 trails, 1-5 trails, 6-10 trails, 11-30 trails, and greater than 30 trails. 
Between 100 and 110 sporozoites were counted per coverslip.  
 
Statistical analyses 






Development of fluorescence intensity assay 
To address the limitations of the classic gliding motility assay, we developed a 
method that assessed gliding motility by quantifying the fluorescence intensity of the CSP 
trails (Fig. 3). The fluorescence intensity assay consisted of taking 20 images that spanned 
the coverslip in order to capture the diversity of trails present (Fig. 4). Using the ROI 
Statistics feature of the program NIS Elements, the sum fluorescence intensity of the CSP 
trails was collected.  
First, we compared the classic assay to the fluorescence intensity assay using 
increasing concentrations of the inhibitory monoclonal antibody 2A10 (Fig. 5A and B). 
There is a significant difference in fluorescence intensity between 0 µg/mL and 5 µg/mL 
of 2A10 (p<0.0001) and between 5 µg/mL and 10 µg/mL of 2A10 (p=0.0008) (Fig. 5A). 
This suggests the marked decrease in fluorescence intensity as the concentration of 2A10 
increases correlates with increased inhibition of gliding motility. To compare the 
fluorescence intensity data with the classic method, the same coverslips were viewed under 
a fluorescent microscope and the trails were counted (Fig. 5B). In the absence of an 
inhibitor almost 80% of the trails viewed contained more than 30 circles and as the 
concentration of 2A10 increased, the number of circles in the trails decreased showing 
inhibition of gliding (Fig. 5B). In order to test the sensitivity of the fluorescence intensity 
assay, another comparison of the two methods was carried out with lower concentrations 
of 2A10 (Fig. 6A). Using the classic method, once again the number of trails decreased as 
the concentration of 2A10 increased (Fig. 6B). Moreover, there is a significant difference 
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in fluorescence intensity between 0 µg/mL and 1 µg/mL of 2A10 (p<0.0001), 1µg/mL and 
2.5 µg/mL (p=0.002), and between 2.5 µg/mL and 5 µg/mL of 2A10 (p<0.0008) (Fig. 6B). 
This suggests that not only does the fluorescence intensity assay correlate with the classic 
assay at lower concentrations of an inhibitory antibody but it is also sensitive enough to be 
able to significantly differentiate changes in inhibition that might not be detected by eye 
and enables better statistical analyses. 
 
In order to confirm the effects of inhibition observed using 2A10, we carried out an 
experiment with cytochalasin D, an actin polymerization inhibitor that prevents motility 
[6] (Fig. 7A). When sporozoites were treated with cytochalasin D they could not glide and 
the low fluorescence intensity observed was due to the parasites being stained (Fig. 7A). 
The inhibition of fluorescence seen using cytochalasin D was comparable to the inhibition 
observed with 10µg/mL 2A10 (Fig. 7A). It is possible that the inhibition observed in our 
experiments was due to competition between the inhibitory 2A10 and the biotinylated 
2A10 used to label the trails. Since they recognize the same epitope, the inhibitor may bind 
to CSP in the trails and obscure their labeling by biotinylated 2A10. In order to address this 
concern, we carried out a similar experiment using 2A10 as the inhibitory antibody but 
with a different detection antibody. The anti-C antibody we used detects the C terminal of 
CSP (Fig. 7B). Since a marked decrease in fluorescence intensity was still observed with a 
different detection antibody, we have greater confidence that the fluorescence intensity 
assay is able to correctly detect a decrease in gliding motility (Fig. 7B). Inhibition with 
2A10 seems to be similar to inhibition with 2A10, however due to increased background 




In order to look at the reproducibility of the fluorescence intensity assay, we carried 
out an experiment comparing the inhibition observed with untreated sporozoites, 
sporozoites treated with either human IgG or α-Pfs 25, and sporozoites treated with 2A10. 
Pfs 25 is a zygote/ookinete surface protein [27] and therefore the humanized mAb α-Pfs 
25 should not show any inhibition of motility in P. falciparum sporozoites. Human IgG 
was also used as a negative control. We normalized the fluorescence intensity of α-Pfs 25 
and 2A10 to the mean of the untreated control of each replicate (Fig. 8). Over 13 
experiments, the assay seems to show strong consistency between experiments, giving us 
confidence in the reproducibility of the data. Hence, we decided to proceed with using the 




















Figure 3. Schematic of the fluorescence intensity assay. Pictorial representation of method 
used to quantify CSP trails. P. falciparum sporozoites were isolated and incubated in 
3%BSA/DMEM for 30 min at 25°C. Sporozoites were added to wells pre-coated with 
2A10 and allowed to glide for 1 hr at 37°C in 5% CO2 incubator. After fixation and 
staining, sporozoites were imaged and fluorescence intensity was quantified using the 




















Figure 4. Examples of gliding motility images collected. Images of gliding motility 
showing the range of trails observed in untreated versus antibody treated sporozoites. 






















Figure 5. Comparison of the classic trail gliding assay to the fluorescence intensity assay. 
(A) Sporozoites were treated with the indicated of mAb 2A10 and then added to wells. 
Sporozoites were allowed to glide for 1 hr after which CSP trails were stained, 20 images 
were acquired, and their fluorescence intensity quantified. Each dot represents total 
fluorescence intensity of 1 image. (B) The same wells were quantified using the classic 





















Figure 6. Comparison between the fluorescence intensity assay and classic gliding motility 






















Figure 7. Verification of fluorescence intensity assay using another inhibitor and a 
different detection antibody. (A) Sporozoites were treated with 1 µM cytochalasin D to 
inhibit gliding and then stained as normal.  (B) Sporozoites were stained with a detection 
antibody against the C terminus of CSP to verify that inhibition of gliding was not due to 




Figure 8. Reproducibility of fluorescence intensity assay. Sporozoites were pre-treated 
with 2A10 or a control antibody. The fluorescence intensity of the treated wells was 
normalized to the mean of its relative untreated control. The concentration of 2A10 was 10 
μg/mL and the concentrations of human IgG and α-Pfs 25 were 50 μg/mL. Data are from 





Testing of the PATH MVI human monoclonal antibodies 
Since the fluorescence intensity assay allows for much faster quantification of 
gliding motility, we decided to scale up the assay to medium throughput by using all 24 
wells in a 24 well plate. This allowed for 3 controls and a maximum of 21 monoclonals to 
be tested per experiment. For ease of comparison of all the monoclonals between 
experiments, the data of each monoclonal has been normalized to the mean of α-Pfs 25 of 
its relative experiment. Each monoclonal was tested at a concentration of 50 µg/mL. 
Testing of mAbs targeting 11 different antigens was performed. The antigens are blinded 
but their HEPA numbers are given below.  
 
HEPA 103 and HEPA 106 
20 HEPA 103 and 21 HEPA 106 monoclonal antibodies were tested (Fig. 9A and 
B). None of the monoclonals showed marked inhibition and therefore were not selected for 
further testing. 
 
HEPA 112 and HEPA 113 
22 HEPA 112 and 12 HEPA 113 monoclonals were tested (Fig. 10A and B). mAbs 
1804, 1787, and 1803 showed some inhibition but none were selected by PATH for 







HEPA 120 and HEPA 126 
9 HEPA 120 and 13 HEPA 126 monoclonals were tested (Fig. 11A and B). None 
of the monoclonals showed marked inhibition of gliding and therefore were not selected 
for further testing. 
 
HEPA 121 and HEPA 124 
11 HEPA 121 and 18 HEPA 124 mAbs were tested (Fig. 12A and B). From the 
HEPA 121 monoclonals, mAbs 1950, 1955, 1937, and 1948 were selected for repeated 
testing (Fig. 12A). 1950 and 1948 seemed to show approximately 50% inhibition of gliding 
upon initial testing but this inhibitory effect seemed to disappear when the experiments 
were repeated (Fig. 12A). A similar effect was seen when mAbs 2318 and 2325 from 
HEPA 124 were tested (Fig. 12B). Ultimately, none of the monoclonals from HEPA 121 
and 124 showed consistent inhibition and were not selected by PATH for testing in mouse 
models. 
 
HEPA 109 and HEPA 122 
11 HEPA 109 and 15 HEPA 122 mAbs were tested (Fig. 13A and B). From HEPA 
109, mAbs 2382, 2394, 2402, 2373, and 2361 were tested more than once (Fig. 13A). mAb 
2373 was selected by PATH for progressing to the next experimental phase of testing since 
at least 40-45% inhibition was observed in 3 separate experiments (Fig. 13A). Apart from 
2240 and 2224, all of the mAbs in HEPA 122 were tested more than once (Fig. 13B). 
Although 2211 was tested 4 times and showed 40-75% inhibition, PATH did not select it 





Out of 21 HEPA 125 mAbs, 13 were tested more than once (Fig. 14). Several mAbs 
(2153, 2171, 2156, 2169) showed a pattern of being markedly inhibitory upon initial testing 
but less so when additional experiments were performed (Fig. 14). 2175, 2176, 2178, and 
2162 were selected by PATH for testing in mouse models since they consistently showed 






Figure 9.Fluorescence intensity of HEPA103 and HEPA 106 normalized to the mean 





Figure 10.Fluorescence intensity of HEPA112 and HEPA 113 normalized to the mean 











Figure 11.Fluorescence intensity of HEPA120 and HEPA 126 normalized to the mean 






Figure 12.Fluorescence intensity of HEPA121 and HEPA 124 normalized to the mean 




Figure 13. Fluorescence intensity of HEPA122 and HEPA 109 normalized to the mean 
fluorescence intensity of α-Pfs 25. HEPA 109. mAb 2373 was selected by PATH MVI for 




Figure 14.Fluorescence intensity of HEPA 125 normalized to the mean fluorescence 
intensity of α-Pfs 25. mAbs 2175, 2176, 2162, and 2178 were selected by PATH MVI for 





A new method for quantifying gliding motility has been described here and based 
on experimental data, the fluorescence intensity assay seems to be a useful in vitro method 
of assessing antibody based vaccines. We believe that our assay can be used to accurately 
assess antibody mediated inhibition of gliding motility. Our method of quantifying 
fluorescence intensity of CSP trails has been shown to be both sensitive to very low 
concentrations of inhibitor and replicable. Statistical analyses is also much easier due to 
the nature of the fluorescence intensity data. We have also addressed the possibility that 
the 2A10 primary antibody was interfering with detection of trails; our data shows 
inhibition of inhibition of gliding motility both with another inhibitor (cytochalasin D) and 
with another primary antibody (anti-C). Another potential verification of the fluorescence 
intensity assay is that additional experiments can be carried out with a mutant TRAP-Val 
parasite that displays impaired gliding. We would expect to see decreased fluorescence 
intensity in the mutant compared to wild type sporozoites.  
Monoclonal antibodies 2373, 2175, 2176, 2162, and 2178 were selected by PATH 
MVI for further testing. Future experiments for the project will involve the 5 antibodies 
being tested in mice with humanized livers and observing if passive administration of the 
mAbs are able to convey some form of immunity against P.falciparum in mice. 4 out of 
the 5 mAbs deemed to show at least 50% inhibition of gliding come from HEPA 125; this 
suggests that the HEPA 125 antigen might be a potential vaccine target. In order to confirm 
that the inhibition seen in the 5 mAbs is due solely to the antibodies binding to the P. 
falciparum sporozoites and inhibiting their gliding, an additional control could be carried 
32 
 
out where the mAbs are tested with P. berghei sporozoites. Ideally, we would not see the 
same levels of inhibition as the mAbs would not bind to the parasites. Our data suggests 
that the majority of the 188 mAbs we tested do not inhibit gliding motility consistently.  
An interesting trend seen several times when testing monoclonals from HEPA 125, 
121, 124, and 109 was that the first test showed marked inhibition of gliding motility but 
subsequent tests did not. A potential reason for this could be that antibodies were freshly 
thawed before the first test and then left at 4 in the fridge for subsequent experiments. 
Perhaps the concentration of the antibodies changed while in the fridge due to sticking to 
the tube or lost the ability to bind to sporozoites as efficiently. This could explain why 
freshly thawed antibodies were more potent inhibitors of gliding. Another reason for this 
could be batch to batch variation of sporozoite motility.  
Due to project time constraints many antibodies were only tested once and based 
on initial data, antibodies were selected for repeated testing. PATH also directed us to 
repeat certain mAbs based on data from the other in vitro tests that were being carried out 
in other labs. This could be seen as biasing the results toward mAb candidates that were 
suspected to be inhibitory. Ideally, we would like to test all the antibodies 3 times to be 
certain that natural variation in gliding or the freshly thawed antibody hypothesis described 




TRAP STAINING OF NON-GLIDING AND GLIDING SPOROZOITES 
INTRODUCTION 
CSP uniformly coats the surface of the sporozoite and has multiple functions 
throughout the pre-erythrocytic stage of malaria [19]. The structure of CSP consists of an 
N terminal domain containing a proteolytic cleavage site [19], a repeat region, and a TSR 
domain in the C terminal region (Fig. 15B). A KLKQP sequence is found at the start of the 
repeat region and is highly conserved among all Plasmodium species (Fig. 15A) [10, 14]. 
The TSR domain consists of a 60 molecule long region that has cell adhesion properties 
(Fig. 15B) [19]. The repeat region of CSP in P. berghei consists of 3 distinct repeated 
sequences NPNDPPP, NANDPPP, and PQPQ (Fig. 15A). Studies have shown that CSP 
plays a vital role in sporozoite infectivity of salivary glands and sporozoite development 
[8, 13, 21]. However, the precise role of the repeat region is still being studied. The 
complete deletion of the repeat region or the repeat region and N terminal has been shown 
to lead to impaired sporozoite development but there was no effect on oocyst formation 
[13]. The ∆Rep mutant produced sporozoites but they were unable to mature and the 
∆N∆Rep mutant was unable to produce any sporozoites [13]. This suggests that the repeat 
region is vital for sporozoite development perhaps playing a structural role or affecting 
other sporozoite membrane proteins [13].  
In order to explore the more subtle phenotypes of the repeat region, our lab generated 
5 mutant parasite lines (Fig. 15B). In ∆Rep1, ∆Rep2, and ∆Rep3 their respective repeat 
region was deleted. ∆DtoN had the aspartic acid residues switched to asparagine in order 
to change the charge of the residues but maintain structure. ∆Scr had the repeats randomly 
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scrambled throughout the repeat region. An RCon (not shown) mutant was also generated 
in order to control for transfection.  
Our lab conducted paired live gliding assays in order to compare mutant motility to 
wild type controls (Fig. 16A and B, unpublished data [5]). In the rodent model used, the 
majority of WT sporozoites were shown to glide in a circular fashion and this was also 
seen in ∆Rep1 and ∆Rep3 (Fig. 16A), suggesting that the first and third repeat regions 
might not play as important of a role in motility. This was corroborated by measuring the 
median speed of sporozoites in live gliding assays (Fig. 16B). WT, ∆Rep1, and ∆Rep3 
sporozoites glide at a median speed of approximately 1.5µm/sec suggesting that the 
mutants are gliding in the same manner as WT. However, ∆Rep2 and ∆Scr sporozoites 
mostly displayed a disrupted waving or patch gliding motility (Fig. 16A). This suggests 
that the second repeat region is required for normal gliding motility and scrambling the 
repeats results in the loss of normal motility as well. ∆Rep2 and ∆Scr have a significantly 
lower median speed (Fig. 16B), supporting the hypothesis that patch and wave gliding are 
irregular and that these two mutants have a disrupted motility. ∆DtoN seems to show a 
subtler, intermediate phenotype where sporozoites show slightly greater levels of patch and 
wave gliding than the more severely affected mutants but the majority of parasites still 
glide in a circular manner (Fig. 16A). The median speed of ∆DtoN sporozoites is 
significantly lower than WT but not as low as ∆Rep2 and ∆Scr suggesting that ∆DtoN is 
not as efficient at circular gliding as WT but still capable of doing so (Fig. 16B).  
Our lab has also investigated the adhesion site turnover of our mutant parasites in order 
to investigate how mutating CSP affects sporozoite ability to attach to an extracellular 
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substrate and how greatly adhesion site turnover affects motility (Fig. 17A and B, 
unpublished data). Using reflection interference contrast microscopy (RICM), we observed 
that WT, ∆Rep1, and ∆Rep3 sporozoites show a similar turnover rate of 22-32 adhesion 
sites/2.5 min (Fig. 17B). However, ∆DtoN, ∆Rep2, and ∆Scr show significantly lower 
turnover rates with ∆Rep2 and ∆Scr showing more severe phenotypes (Fig. 17B). The lack 
of adhesion site turnover supports the previously median motility speed data that showed 
that ∆Rep2 and ∆Scr moved much slower than WT.  
Since adhesion sites were shown to be affected by CSP mutation, we wanted to explore 
how TRAP is distributed on the surface of our mutants. Thrombospondin-related 
anonymous protein (TRAP) is a type I transmembrane protein found in the micronemes of 
the sporozoite [19]. Its extracellular domain consists of two adhesion domains: an A 
domain and a TSR [11]. It has been suggested that TRAP connects the actomyosin motor 
complex of the sporozoite to extracellular proteins [21] and sporozoite motility depends on 
TRAP adhesion turnover [11]. When the parasite takes part in gliding motility, the 
sporozoite moves forwards and TRAP and the intracellular motor moves backwards [11]. 
Using this model and previous studies, we believe the movement of TRAP from the 
posterior end of the sporozoite is necessary for gliding motility [11]. When TRAP is 
deleted, sporozoites are unable to move [11]. It is been shown a rhomboid protease is 
required to cleave TRAP in order for it to be shed and if the rhomboid-cleavage site is 
mutated, not only is TRAP not shed but gliding motility and infectivity as reduced [11, 26]. 
These are phenotypes are similar to what we have observed in our CSP mutant parasites. 
However, currently there is no known interaction between CSP and TRAP and it is unclear 
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how mutations in the repeat regions would impact TRAP shedding. In order to investigate 
the link between CSP and TRAP adhesive interactions, here we demonstrate the TRAP 












Figure 15. Schematic representations of CSP and the CSP repeat amino acid sequence. 
A) The amino acid sequence of the P. berghei CSP repeats showing the KLKQP 
sequence and the 3 repeat regions. B) Schematic comparisons of WT CSP to our mutant 
parasites. ∆Rep1, ∆Rep2, and ∆Rep3 have their respective repeat region deleted. ∆DtoN 

















Figure 16. Categorization of motility and median speed seen in wild type and mutant 
parasites in live gliding assays [5, unpublished data]. A) Paired live gliding assays were 
carried out with wild type and mutant sporozoites and 4 categories of motility were 
















Figure 17. Turnover of adhesion sites in wild type and mutant parasites as analyzed by 
RICM [5, unpublished data]. A) Visualization of adhesion site turnover over time. 
Adhesion sites are shown as dark patches. B) Differences in adhesion site turnover between 





Generation of mutant parasites and parasite transfection 
Mutant parasites were generated as described previously [13]. For each of the 
mutants the endogenous csp gene was replaced with a csp gene in which the repeat 
sequence of CSP was truncated, the repeats were scrambled, or the charge of residues 
reversed by converting aspartate to asparagine. Parasites were transfected as described 
previously [13].  
Parasite development in Anopheles stephensi  
Parasites were allowed to develop in the mosquito following a blood meal as 
described previously [13]. Between day 21 and 22 post blood meal, salivary glands were 
collected and sporozoites were isolated. 
Immunofluorescence assays 
Glass coverslips were placed in two 24 well plates, one for gliding and one for non-
gliding. Mosquitoes were dissected in L-15 (Leibowitz 15) and salivary glands were 
obtained. The salivary glands were pelleted by spinning down for 6 seconds. The media 
was removed and replaced with 200 µL of fresh, cold L-15. The sporozoites were then 
isolated and counted. 400 µL containing 10000-50000 sporozoites in L-15 was then added 
to each well. The sporozoites were spun for 4 minutes at 300g with an acceleration of 3 
minutes and no brake deceleration.  
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The media was removed from the non-gliding wells and the sporozoites were fixed 
with cold 4% paraformaldehyde for 1 hour at room temperature. After the removal of the 
media from the gliding wells, 400 µL of 2% BSA/L-15 pH 7.4 was added per well. The 
gliding plate was placed in a 5% CO2 incubator for 1 hour to allow sporozoites to glide. 
After gliding, the sporozoites were fixed as per the non-gliding well. 
  After fixing, the wells were washed 3 times with 1x PBS pH 7.4. The wells were 
blocked with 1%BSA/5% goat serum/BSA for 1 hour at 37°C. The wells were then stained 
with primary antibody for 1 hour at 37°C, washed 3 times with PBS, and then stained with 
secondary antibody for 1 hour at 37°C. The primary antibodies used were either polyclonal 
α-TRAP (1:100 dilution) or IgG purified α-TRAP (1:100 dilution). The secondary used 
was a goat anti-rabbit (H+L) highly cross adsorbed antibody conjugated to Alexa fluor 594 
[A-11037]. After staining, the wells were washed 3 times with PBS. The coverslips were 
carefully removed from the wells, allowed to dry for 10 minutes, and then mounted to 
slides with ProLong Gold antifade DAPI mounting media overnight. The coverslips were 
then sealed with clear nail polish and imaged using the 100x oil objective of a fluorescent 
microscope. Sporozoites were picked using bright field and categorized using the 
fluorescent channel. Over 100 sporozoites were counted and categorized according to the 
following: no stain, punctate, patched, and whole stain.  
Statistical analyses 
To determine significance of results, paired T-tests were carried out with a 95% 




Four categories of TRAP staining were observed in wild type sporozoites in non-
gliding and gliding conditions: unstained, punctate staining, patch staining, and whole 
staining. (Fig. 18 and Fig. 19). Unstained signified no stain on the sporozoite and punctate 
staining signified a dotted staining (Fig. 18). Patch staining signified a large patch in either 
the center of the sporozoite or at the posterior end (Fig. 19). Whole staining signified the 
entire parasite being fluorescent. There seem to be marked differences in TRAP staining 
between non gliding and gliding wild type sporozoites (Fig. 20). In non-gliding conditions 
there was a significantly greater percentage of unstained sporozoites (p<0.0001) whereas 
in gliding conditions, there was a significantly greater percentage of patch stained 
sporozoites (p<0.0001). Gliding sporozoites also seemed to show a significantly greater 
(p=0.0091, p=0.0231) percentage of punctate and whole staining (Fig. 20). This data 
supports the idea that TRAP is shed when sporozoites start to move.  
In order to address concerns that 1 hour of gliding might be too long and might lead 
to sporozoite death, we carried out a side by side comparison of sporozoites glidng for 20 
minutes and 1 hour (Fig. 21). This experiment was also carried out using an IgG purified 
antibody to TRAP in order to minimize background. As observed before the percent of 
unstained sporozoites in non-gliding conditions is 55% and this number decreases as 
sporozoites begin to glide and secrete TRAP. A greater percentage of patched sporozoites 
is seen in the 1 hour gliding condition compared to the 20 minute gliding condition (Fig. 
21). Less than 10% of sporozoites are whole stained under all the 3 conditions and the 
percent of punctate stained sporozoites does not seem to vary between 20 minutes and 1 
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hour conditions (Fig. 21). Since the percent of punctate and whole stained sporozoites was 
quite small, for ease of comparison going forward we have grouped punctate, patched, and 
whole stained sporozoites as just ‘stained’. 
In order to further investigate TRAP staining, mutant sporozoite IFAs were 
performed with a WT control (Fig. 22A and B). Non-gliding ∆Rep1, ∆Rep3, ∆DtoN, and 
RCon sporozoites show a similar percent stained to that of their non-gliding WT controls 
where approximately 30-40% of parasites show some form of TRAP stain (Fig. 22A). ∆Scr 
shows the most marked difference from where less than 10% of non-gliding sporozoites 
show TRAP staining compared to 30% stained in its WT control (Fig. 22A). In gliding 
conditions, ∆Rep1, ∆Rep3, and RCon sporozoites show a similar percent stained compared 
to their WT controls where over 75% of sporozoites show TRAP staining. (Fig. 22B). 
Gliding ∆DtoN sporozoites seem to show a slightly lower percentage of stained parasites 
compared to WT (Fig. 22B). ∆Scr again shows the greatest deviation from WT with less 




Figure 18. Examples of TRAP staining observed in sporozoites. TRAP is stained red. Scale 




Figure 20. Examples of patched TRAP staining observed in sporozoites. TRAP is stained 




 Figure 20. Comparison of wild type sporozoite TRAP staining patterns in non-gliding and 
gliding conditions. Sporozoites were allowed to glide on glass coverslips for 1 hr after 
which they were fixed and stained. Coverslips were imaged and TRAP staining patterns of 





Figure 21. Comparison of TRAP staining patterns in sporozoites gliding for 20 min vs 1 
hr. Non gliding sporozoites were instantly fixed with 4% PFA after parasites were spun 
onto coverslips. Gliding sporozoites were incubated at 37°C for 20 min then fixed. In a 



















Fig. 22. Percent of mutant sporozoites that are stained compared to their WT controls in 
non-gliding and gliding conditions. A) Percent of TRAP stained sporozoites in non-gliding 
conditions. B) Percent of TRAP stained sporozoites in gliding conditions. 




Here we provide evidence that motility phenotypes observed in WT and mutant 
sporozoites might be linked to TRAP secretion during gliding. We carried out IFAs of 
mutant sporozoites with a WT control in gliding and non-gliding conditions and stained 
the sporozoites with an antibody against TRAP. We categorized sporozoite staining 
patterns according to four categories: unstained, punctate staining, patch staining, and 
whole staining. After observing that the key differences in non-gliding and gliding 
sporozoites was between no stain and patch staining, with punctate and whole staining seen 
in lower numbers, we decided to group all punctate, patch, and wild type staining into a 
single category called ‘stained’. 
We consistently observed that in WT non-gliding sporozoites 55-65% of parasites 
are unstained and the remainder of sporozoites show some type of staining. This could 
mean that even in non-gliding conditions the sporozoites have begun to glide and release 
TRAP. There is a 40% range in the percent unstained WT sporozoites in non-gliding 
conditions. This is most likely due to handling differences in preliminary experiments and 
improved handling over time led to fewer sporozoites starting to glide before fixation. In 
order to address the concern that some sporozoites in non-gliding conditions are moving, 
the assay needs to be optimized. Future experiments to decrease gliding in non-gliding 
conditions are carrying out the initial stages of the assay in a cold room, fixing with PFA 
at 4°C, and fixing for 30 minutes instead of 1 hour to prevent transformation of the parasite. 
We would also change the centrifuge time settings so that sporozoites are immediately spun 
down onto coverslips without an acceleration or deceleration phase. Another aspect of the 
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assay that needs to be optimized is minimizing background staining due to mosquito debris. 
We have tried to address this by switching from a polyclonal α-TRAP to an IgG purified 
α-TRAP. Nevertheless, it is not clear if punctate staining is a consistently reliable indicator 
of TRAP secretion on the membrane; it is possible that some punctate staining may be due 
to background.  
There was concern that 1 hour of gliding was too long and that sporozoites were 
dying so we carried out a side by side experiment comparing gliding between 20 mins and 
1 hour. According to our data, we believe that continuing with 1 hour of gliding is a better 
option as the patch staining phenotype is more pronounced. If sporozoites are only allowed 
to glide for 20 mins, sporozoites might have less TRAP secretion and subtler phenotypes 
between mutants might not be observed. A future experiment that could be carried out in 
order to verify the whole staining patterns would be to carry out live/dead staining; this 
would allow us to observe whether whole staining is due to TRAP secretion while gliding 
or whether the sporozoites have died during the assay. 
We saw significant changes in the percentages of stained WT sporozoites between 
non-gliding and gliding conditions suggesting that TRAP is only released from the 
micronemes and cleaved by the rhomboid protease when sporozoites start gliding. It is 
challenging to draw definite conclusions between WT and mutant sporozoites because so 
far we only have duplicates of our experiments. However, ∆Rep1, ∆Rep3, and RCon 
sporozoites seem to show similar percent stained to WT in gliding conditions. This 
corroborates live gliding and adhesion site turnover data from our lab and suggests that in 
these mutants, TRAP is deposited on the surface of the sporozoite when gliding occurs and 
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shed in a similar manner to WT. ∆DtoN seems to display slightly lower percent stained in 
gliding conditions than WT. This supports the subtle phenotypes seen in our live gliding 
and adhesion site turnover data where ∆DtoN sporozoites have a lower adhesion site 
turnover rate than WT. However, more replicates are required in order for us to have more 
confidence in the data.  
The marked difference between ∆Scr and WT TRAP staining in both non-gliding 
and gliding conditions could suggest that TRAP is not being secreted onto the surface of 
the sporozoite. When taken in the context of the previously described live gliding and 
adhesion site turnover data, it is possible that TRAP is not secreted in ∆Scr due to the 
sporozoite attaching to the substrate but not being able to glide in a circular fashion. By 
carrying out primarily patch and wave gliding and not turning over as many adhesion sites, 
perhaps TRAP is unable to be distributed on the surface of the sporozoite and shed. It is 
also possible that the ∆Scr sporozoites are attached to the substrate but not gliding at all, 
although this seems less likely due to the fact that the parasites are able to glide in live 
gliding assays. We intend to test ∆Rep2 in future; if a similar pattern to ∆Scr is seen in 
∆Rep2 (a mutant that is also shows patch and wave gliding and low adhesion site turnover), 
we would be able to have more confidence in our hypothesis that sporozoites first attach to 
the substrate and then initiate gliding and shedding of TRAP. In order to confirm that ∆Scr 
does not lack TRAP, a future experiment where sporozoites are permeabilized needs to be 
carried out. This will both allow us to be sure that any TRAP staining phenotypes seen in 
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